IGC Pharma, Inc.
IGC
$0.3262
$0.01986.46%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -37.62% | 51.47% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -37.62% | 51.47% | |||
| Cost of Revenue | -28.50% | 96.33% | |||
| Gross Profit | -47.47% | 21.47% | |||
| SG&A Expenses | 8.55% | -36.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -1.70% | -17.79% | |||
| Operating Income | -6.70% | 25.74% | |||
| Income Before Tax | -6.52% | 27.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.52% | 27.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.52% | 27.80% | |||
| EBIT | -6.70% | 25.74% | |||
| EBITDA | -6.56% | 26.86% | |||
| EPS Basic | -4.42% | 30.89% | |||
| Normalized Basic EPS | -4.26% | 30.20% | |||
| EPS Diluted | -4.42% | 30.89% | |||
| Normalized Diluted EPS | -4.26% | 30.20% | |||
| Average Basic Shares Outstanding | 2.14% | 4.39% | |||
| Average Diluted Shares Outstanding | 2.14% | 4.39% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
